Long Shortz with Neurizon Therapeutics: Clinical hold lift on the horizon

Neurizon Therapeutics plans to implement several initiatives to get the clinical hold lifted of its IND application for NUZ-001.

Stockhead’s Tylah Tully chats with Neurizon Therapeutics (ASX:NUZ) managing director Michael Thurn about the company's goal of achieving an Investigational New Drug application for NUZ-001.

The company has been in discussion with the US FDA since February, working to get the clinical hold lifted for NUZ-001, a potentially life changing treatment for neurodegenerative
diseases.

Watch the video to see the initiatives Neurizon is taking.

This video was developed in collaboration with Neurizon Therapeutics, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.

Originally published as Long Shortz with Neurizon Therapeutics: Clinical hold lift on the horizon